FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eduardo Diaz-Rubio

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Spain

Co-author Network

Publications

TOP 3
Alejandro Romera-Lopez; Trinidad Caldes; Nayade del Prado; Eduardo Diaz-Rubio; Manuel Fuentes; Beatriz Perez-Villamil
Effect of high RNA concentrations in real time reverse transcription quantitative polymerase chain reaction (RT-qPCR) yields.
M Martin; B Oliva; J Puente; J M Román; A Romero; J A Vidart; T Caldés; Antonio Casado; M C U Cheang; J de la Torre; Eduardo Diaz-Rubio; V Furio; J A García-Saenz; X He; J A López García-Asenjo; Sara Lopez-Tarruella; C M Perou
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Paloma Ortega; Alberto Moran; Tamara Fernandez-Marcelo; Carmen de Juan; Cristina Frias; José-Antonio Lopez-Asenjo; Andrés Sanchez-Pernaute; Antonio Torres; Eduardo Diaz-Rubio; Pilar Iniesta; Manuel Benito
MMP-7 and SGCE as distinctive molecular factors in sporadic colorectal cancers from the mutator phenotype pathway.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eduardo Diaz-Rubio (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Alejandro Romera-Lopez; Trinidad Caldes; Nayade del Prado; Eduardo Diaz-Rubio; Manuel Fuentes; Beatriz Perez-Villamil
Effect of high RNA concentrations in real time reverse transcription quantitative polymerase chain reaction (RT-qPCR) yields.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2012;50(9):1689-91.
2011: M Martin; B Oliva; J Puente; J M Román; A Romero; J A Vidart; T Caldés; Antonio Casado; M C U Cheang; J de la Torre; Eduardo Diaz-Rubio; V Furio; J A García-Saenz; X He; J A López García-Asenjo; Sara Lopez-Tarruella; C M Perou
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Breast cancer research and treatment 2011;128(1):127-36.
2010: Paloma Ortega; Alberto Moran; Tamara Fernandez-Marcelo; Carmen de Juan; Cristina Frias; José-Antonio Lopez-Asenjo; Andrés Sanchez-Pernaute; Antonio Torres; Eduardo Diaz-Rubio; Pilar Iniesta; Manuel Benito
MMP-7 and SGCE as distinctive molecular factors in sporadic colorectal cancers from the mutator phenotype pathway.
International journal of oncology 2010;36(5):1209-15.
2007: Jan B Vermorken; José M Trigo; Ricardo Hitt; Piotr Koralewski; Eduardo Diaz-Rubio; Frédéric Rolland; Rainald Knecht; Nadia Amellal; Armin Schueler; José Baselga
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2171-7.
2007: Carmen Cañadas; Ana Sánchez de Abajo; Juan Manuel Fernández; Miguel Martín; Eduardo Diaz-Rubio; Trinidad Caldés; Miguel de la Hoya
Molecular haplotyping of tandem single nucleotide polymorphisms by allele-specific PCR.
Analytical biochemistry 2007;364(2):153-8.
2006: Cristina Garcia-Aranda; Carmen de Juan; Antonio Diaz-Lopez; Andres Sanchez-Pernaute; Antonio-Jose Torres; Eduardo Diaz-Rubio; Jose L Balibrea; Manuel Benito; Pilar Iniesta
Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma.
Cancer 2006;106(3):541-51.
2006: Javier Sastre; Jose Angel Garcia-Saenz; Eduardo Diaz-Rubio
Chemotherapy for gastric cancer.
World journal of gastroenterology : WJG 2006;12(2):204-13.
2005: Ana Sánchez de Abajo; Miguel de la Hoya; Alicia Tosar; Javier Godino; Juan Manuel Fernández; Jose-Lopez Asenjo; Beatriz-Perez Villamil; Pedro-Perez Segura; Eduardo Diaz-Rubio; Trinidad Caldes
Low prevalence of germline hMSH6 mutations in colorectal cancer families from Spain.
World journal of gastroenterology : WJG 2005;11(37):5770-6.
2005: Chris J Twelves; Charles A Butts; Jim Cassidy; Thierry Conroy; Fillippo de Braud; Eduardo Diaz-Rubio; Josep Tabernero; Patrick Schoffski; Arie Figer; Rene Brunet; Johannes Grossmann; Alberto Sobrero; Eric Van Cutsem
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Clinical colorectal cancer 2005;5(2):101-7.
2005: Albert Abad; Alfredo Carrato; Matilde Navarro; Javier Sastre; Andrés Cervantes; Antonio Antón; Mercedes Martinez-Villacampa; Eugenio Marcuello; Bartomeu Massutí; Enrique Aranda; José Luis Manzano; José Luis Guallar; Eduardo Diaz-Rubio
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
Clinical colorectal cancer 2005;4(6):384-9.
2004: Miguel Martin; Jesus García-Donas; Antonio Casado; Isabel de la Gándara; Pedro Pérez-Segura; Jose-Angel García-Saenz; Gabriel Ibáñez; Belen Loboff; Gemma García-Ledo; Fernando Moreno; Enrique Grande; Eduardo Diaz-Rubio
Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.
Clinical breast cancer 2004;5(5):353-7.
2004: Trinidad Caldés; Javier Godino; Ana Sanchez; Cesar Corbacho; Miguel de la Hoya; Jose Lopez Asenjo; Carmen Saez; Julian Sanz; Manuel Benito; Santiago Ramon Y Cajal; Eduardo Diaz-Rubio
Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
Oncology reports 2004;12(3):621-9.
2004: Albert Abad; Bartomeu Massutí; Javier Gallego; Ana L Yuste; José Luis Manzano; Alfredo Carrato; Antonio Antón; Xavier Marfa; Eduardo Diaz-Rubio
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Anti-cancer drugs 2004;15(5):469-71.
2004: Eduardo Diaz-Rubio
New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers.
The oncologist 2004;9(3):282-94.
2003: M Martin; A Villar; A Sole-Calvo; R Gonzalez; Bartomeu Massuti; J Lizon; Carlos Camps; Alfredo Carrato; Antonio Casado; M T Candel; Joan Albanell; J Aranda; B Munarriz; J Campbell; Eduardo Diaz-Rubio
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):833-42.
2002: Trinidad Caldes; Miguel de la Hoya; Alicia Tosar; Sara Sulleiro; Javier Godino; D Ibañez; M Martin; Pedro Perez-Segura; Eduardo Diaz-Rubio
A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes.
Journal of medical genetics 2002;39(8):e44.
2002: Trinidad Caldes; Javier Godino; Miguel de la Hoya; Iciar Garcia Carbonero; Pedro Perez-Segura; Charis Eng; Manuel Benito; Eduardo Diaz-Rubio
Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain.
International journal of cancer. Journal international du cancer 2002;98(5):774-9.
2001: Javier Godino; Miguel de la Hoya; Eduardo Diaz-Rubio; Manuel Benito; Trinidad Caldés
Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis colorectal cancer families from Spain.
Human mutation 2001;18(6):549.
2000: Miguel Martín; Antonio Casado; J A Macias; Iciar Garcia Carbonero; J A Garcia-Saenz; M Oruezabal; Isabel Manrique; Eduardo Diaz-Rubio
Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study.
American journal of clinical oncology 2000;23(6):617-21.
2000: Joaquim Bellmunt; Vicente Guillem; Luis Paz-Ares; José Luis González-Larriba; Joan Carles; Eduard Batiste-Alentorn; Alberto Sáenz; Marta López-Brea; Albert Font; Miquel Nogué; R Bastús; Miguel Angel Climent; Juan J de la Cruz; Joan Albanell; J M Banús; E Gallardo; Eduardo Diaz-Rubio; Hernán Cortés-Funes; José Baselga
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(18):3247-55.
2000: Trinidad Caldés; Javier Godino; Pedro Perez-Segura; Miguel de la Hoya; Eduardo Diaz-Rubio; Manuel Benito
New mutation in the hMSH2 gene in a Spanish Muir-Torre syndrome.
The American journal of gastroenterology 2000;95(9):2389-90.
2000: Trinidad Caldes; Pedro Perez-Segura; Alicia Tosar; Miguel de la Hoya; Eduardo Diaz-Rubio
Low frequency of microsatellite instability in sporadic breast cancer.
International journal of oncology 2000;16(6):1235-42.
2000: Trinidad Caldés; Pedro Perez-Segura; Alicia Tosar; Miguel de la Hoya; Eduardo Diaz-Rubio
Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer.
Teratogenesis, carcinogenesis, and mutagenesis 2000;20(5):283-91.
2000: M Martín; Ana Lluch; Antonio Casado; I Garciía Carbonero; L de Paz; C Esteban; Amelia Insa; R Alfonso; J García-Conde; Eduardo Diaz-Rubio
Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(1):85-9.
1999: A Moreno-Elola; A Aguilar; J M Roman; A Hernandez; M Martin; Eduardo Diaz-Rubio; V Furio; C Fernandez; P De La Fuente; J M San Roman; M Escudero
Prognostic factors in invasive lobular carcinoma of the breast: a multivariate analysis. A multicentre study after seventeen years of follow-up.
Annales chirurgiae et gynaecologiae 1999;88(4):252-8.
1998: Trinidad Caldes; Pilar Iniesta; FJ Vega; Carmen de Juan; J A Lopez; Eduardo Diaz-Rubio; C Fernandez; J Cerdan; Jose L Balibrea; Manuel Benito
Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer.
Oncology 1998;55(3):249-57.
1998: M Martin; Antonio Casado; Pedro Perez-Segura; Iciar Garcia Carbonero; Eduardo Diaz-Rubio
Paclitaxel plus vinorelbine in metastatic breast Ca patients with contraindications to receive anthracyclines.
Oncology (Williston Park, N.Y.) 1998;12(1 Suppl 1):28-30.
1997: José Luis González-Larriba; Iciar Garcia Carbonero; Javier Sastre Valera; Pedro Perez-Segura; Eduardo Diaz-Rubio
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):90-7.
1997: Jose A Lopez-Martin; Antonio Casado; J A López-Martin; A Rodriguez-Lescure; Yago Nieto; F Ayala; Eduardo Diaz-Rubio
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):83-5.
1997: Albert Abad; Matilde Navarro; Javier Sastre; Eugenio Marcuello; Enrique Aranda; Manel Gallén; C Fernandez-Martos; C Martín; Eduardo Diaz-Rubio
A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):53-7.
1997: Agustí Barnadas; C Mendiola; A Casado; A Villar; J Jimeno; M Clerigue; R Rosell; Eduardo Diaz-Rubio; Hernán Cortés-Funes; M García de Paredes
Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study.
European journal of cancer (Oxford, England : 1990) 1997;33(2):312-5.
1997: FJ Vega; Pilar Iniesta; Trinidad Caldés; A Sanchez; JA López; Carmen de Juan; Eduardo Diaz-Rubio; Antonio Torres; Jose L Balibrea; Manuel Benito
p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer.
British journal of cancer 1997;76(1):44-51.
1996: A Fernández-Marcos; Miguel Martín; Jose A Lopez-Martin; A Rodriguez-Lescure; Antonio Casado; J A López Martin; Eduardo Diaz-Rubio
Acute and anticipatory emesis in breast cancer patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1996;4(5):370-7.
1996: Bruno Audhuy; P Cappelaere; M Martin; Andrés Cervantes; Michel Fabbro; A Rivière; David Khayat; H Bleiberg; M Faraldi; N Claverie; Enrique Aranda; Gérard Auclerc; B Audhuy; A Benhammouda; H Bleiberg; L Cals; P Cappelaere; A Cattan; A Cervantes; Bernard Chevallier; Thierry Conroy; Didier Cupissol; J De Grève; Eduardo Diaz-Rubio; J F Seitz
A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
European journal of cancer (Oxford, England : 1990) 1996;32A(5):807-13.
1996: D Machover; Eduardo Diaz-Rubio; A de Gramont; A Schilf; J J Gastiaburu; Silvano Brienza; M Itzhaki; G Metzger; D N'Daw; J Vignoud; Albert Abad; E Francois; Erick Gamelin; Michel Marty; Javier Sastre; Jean-François Seitz; Marc Ychou
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):95-8.
1994: U Bohn; J L Gonzalez; L M Martin; Antonio Casado; Eduardo Diaz-Rubio; P Aragoncillo
Meningeal and brain metastases in primary malignant pericardial mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(7):660-1.
1994: Jose A Lopez-Martin; Eduardo Diaz-Rubio; Antonio Casado; J J Valverde; D Garcia Urra; J A López-Martin; A Rodriguez-Lescure
Prednimustine-induced myoclonus--a report of three cases.
Acta oncologica (Stockholm, Sweden) 1994;33(1):81-2.
1994: Eduardo Diaz-Rubio; E Adrover
Use of granulocyte growth factors in solid tumours.
European journal of cancer (Oxford, England : 1990) 1994;30A(1):120-2.
1993: Miguel Martín; Eduardo Diaz-Rubio; José Luis González-Larriba; Antonio Casado; Javier Sastre; J M López-Vega; JOSE ALMENAREZ; S Dominguez
Ifosfamide in advanced epidermoid head and neck cancer.
Cancer chemotherapy and pharmacology 1993;31(4):340-2.
1993: M Martín; A Casado; A Lluch; E Adrover; Eduardo Diaz-Rubio; J García-Conde
Preliminary results of a phase II trial of chronic oral etoposide in breast cancer.
Cancer treatment reviews 1993;19 Suppl C():47-52.
1992: M Martin; Eduardo Diaz-Rubio; Antonio Casado; J M López Vega; Javier Sastre; JOSE ALMENAREZ
Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial.
American journal of clinical oncology 1992;15(4):348-51.
1992: M Martin; Eduardo Diaz-Rubio; Antonio Casado; S Dominguez; Javier Sastre
Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):430-2.
1991: M Martin; Eduardo Diaz-Rubio; Antonio Casado; J M López Vega
Phase II study of carboplatin in advanced breast cancer: preliminary results.
Seminars in oncology 1991;18(1 Suppl 2):23-7.
1991: Eduardo Diaz-Rubio; M Martin; Rafael Rosell; J J Valerdi; J L Gonzalez-Larriba; J J Barriga
The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial.
Acta oncologica (Stockholm, Sweden) 1991;30(3):339-42.
1990: M Martin; Eduardo Diaz-Rubio; A Sánchez; JOSE ALMENAREZ; J M López-Vega
The natural course of emesis after carboplatin treatment.
Acta oncologica (Stockholm, Sweden) 1990;29(5):593-5.
1990: Eduardo Diaz-Rubio; Enrique Aranda; M Martin; R Gonzalez-Mancha; J Gonzalez-Larriba; Isidoro Barneto
Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(6):727-9.
1990: M Martin; Eduardo Diaz-Rubio
Emesis during past pregnancy: a new prognostic factor in chemotherapy-induced emesis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(2):152-3.
1989: M Martin; Eduardo Diaz-Rubio; Vicente Furió; J Blázquez; JOSE ALMENAREZ; J Fariña
Lethal cardiac toxicity after cisplatin and 5-fluorouracil chemotherapy. Report of a case with necropsy study.
American journal of clinical oncology 1989;12(3):229-34.
1989: A Abad-Esteve; Eduardo Diaz-Rubio; J M Jimeno; Rafael Rosell; A Villar; J L Gonzalez-Larriba
Oral idarubicin in measurable gastric cancer.
American journal of clinical oncology 1989;12(1):14-6.
1989: Eduardo Diaz-Rubio; M Escudero; M Martin-Jimenez; J A Vidart; J L Gonzalez-Larriba; M A Herraiz; J M Lopez Vega; F Bullon
Treatment of advanced ovarian cancer with cisplatin, adriamycin and cyclophosphamide (PAC).
European journal of gynaecological oncology 1989;10(6):424-32.
1988: M Martin-Jimenez; Eduardo Diaz-Rubio; B Sangro; R Marote
Laparotomic eventration or colonic prolapse after chemotherapy-induced emesis.
Journal of surgical oncology 1988;37(3):204-6.
1987: M Martin-Jimenez; Eduardo Diaz-Rubio; B Sangro
Results of two controlled studies on antiemetic combination against vomiting induced by 5-fluorouracil.
Tumori 1987;73(5):499-504.
1987: M Martin-Jimenez; Eduardo Diaz-Rubio; J L Gonzalez Larriba; B Sangro
Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer.
European journal of gynaecological oncology 1987;8(2):98-102.
1986: M Martin-Jimenez; Eduardo Diaz-Rubio; J L Gonzalez Larriba; B Sangro
Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin.
The New England journal of medicine 1986;315(14):894-5.
1986: M Martin-Jimenez; Eduardo Diaz-Rubio
Clinical evaluation of the simultaneous blockade of the dopamine D-2, histamine H-1, and muscarinic cholinergic receptors in cancer chemotherapy-induced emesis: results of a controlled trial.
Cancer chemotherapy and pharmacology 1986;18(2):168-71.
1984: Eduardo Diaz-Rubio; M Martin-Jimenez
Vindesine in the treatment of advanced colorectal cancer: a phase II study.
Cancer treatment reports 1984;68(3):555-6.